JP2022531184A - がんの処置 - Google Patents

がんの処置 Download PDF

Info

Publication number
JP2022531184A
JP2022531184A JP2021564270A JP2021564270A JP2022531184A JP 2022531184 A JP2022531184 A JP 2022531184A JP 2021564270 A JP2021564270 A JP 2021564270A JP 2021564270 A JP2021564270 A JP 2021564270A JP 2022531184 A JP2022531184 A JP 2022531184A
Authority
JP
Japan
Prior art keywords
biomaterial
polymer
agonist
cancer
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021564270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531184A5 (https=
JPWO2020223698A5 (https=
Inventor
マイケル ソロモン ゴールドバーグ，
Original Assignee
スティミット コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スティミット コーポレイション filed Critical スティミット コーポレイション
Publication of JP2022531184A publication Critical patent/JP2022531184A/ja
Publication of JP2022531184A5 publication Critical patent/JP2022531184A5/ja
Publication of JPWO2020223698A5 publication Critical patent/JPWO2020223698A5/ja
Priority to JP2024114666A priority Critical patent/JP2024151337A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021564270A 2019-05-02 2020-05-01 がんの処置 Pending JP2022531184A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024114666A JP2024151337A (ja) 2019-05-02 2024-07-18 がんの処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962842068P 2019-05-02 2019-05-02
US62/842,068 2019-05-02
PCT/US2020/031169 WO2020223698A1 (en) 2019-05-02 2020-05-01 Cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024114666A Division JP2024151337A (ja) 2019-05-02 2024-07-18 がんの処置

Publications (3)

Publication Number Publication Date
JP2022531184A true JP2022531184A (ja) 2022-07-06
JP2022531184A5 JP2022531184A5 (https=) 2023-05-11
JPWO2020223698A5 JPWO2020223698A5 (https=) 2023-05-11

Family

ID=73029386

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021564270A Pending JP2022531184A (ja) 2019-05-02 2020-05-01 がんの処置
JP2024114666A Pending JP2024151337A (ja) 2019-05-02 2024-07-18 がんの処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024114666A Pending JP2024151337A (ja) 2019-05-02 2024-07-18 がんの処置

Country Status (10)

Country Link
US (1) US20220218822A1 (https=)
EP (1) EP3962524A4 (https=)
JP (2) JP2022531184A (https=)
KR (1) KR20220004077A (https=)
CN (1) CN113766929A (https=)
AU (1) AU2020266676A1 (https=)
BR (1) BR112021021699A8 (https=)
CA (1) CA3132653A1 (https=)
IL (1) IL287652A (https=)
WO (1) WO2020223698A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240162725A (ko) * 2023-05-09 2024-11-18 국립부경대학교 산학협력단 아임계 수 가수분해를 이용한 갑각류 유래 올리고키토산의 제조방법, 이를 이용하여 제조된 올리고키토산 및 올리고키토산을 포함하는 약학적 조성물

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230041032A (ko) * 2020-07-17 2023-03-23 서지 테라퓨틱스, 인크. 중합체 복합 제제를 포함하는 제제 및 조성물
AU2021329884A1 (en) * 2020-08-17 2023-02-16 SURGE Therapeutics, Inc. Immune modulation of myeloid derived suppressive cell function for cancer treatment
AU2022212114A1 (en) * 2021-01-30 2023-06-22 SURGE Therapeutics, Inc. Cancer therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018045058A1 (en) * 2016-08-30 2018-03-08 Dana-Farber Cancer Institute, Inc. Drug delivery compositions and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965379A (en) * 1991-07-19 1999-10-12 Cytimmune Sciences Inc. Method for measuring endogenous cytokines
EP0820305A2 (en) 1995-04-04 1998-01-28 Wound Healing of Oklahoma Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant
US6756363B1 (en) 2000-11-17 2004-06-29 Wound Healing Of Oklahoma, Inc. Solutions and films of glycated chitosan
AU2003243608A1 (en) * 2002-06-20 2004-01-06 Royer Biomedical, Inc. Resorbable delivery systems for the treatment of cancer
RU2288730C2 (ru) * 2005-02-22 2006-12-10 Научно-исследовательский институт Эпидемиологии и микробиологии Сибирского отделения Российской академии наук (НИИ ЭМ СО РАМН) Способ лечения онкогинекологических больных и гель для его осуществления
EP1942950A2 (en) * 2005-11-01 2008-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Biodegradable composite for internal local radiotherapy
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
EP3831393A1 (en) 2012-01-20 2021-06-09 Immunophotonics, Inc. Chitosan-derived compositions
US11111316B2 (en) 2012-01-20 2021-09-07 Immunophotonics, Inc. Chitosan-derived compositions
US20160008399A1 (en) * 2013-01-14 2016-01-14 Fred Hutchinson Cancer Research Center Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
WO2017024318A1 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
AU2017255833B2 (en) * 2016-04-25 2022-09-01 Mizhou Hui Application of small-molecule hyaluronic acid fragment
WO2018088933A1 (en) * 2016-11-14 2018-05-17 Limited Liability Company "Panacela Labs" Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018045058A1 (en) * 2016-08-30 2018-03-08 Dana-Farber Cancer Institute, Inc. Drug delivery compositions and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JONG-JIN KIM, JOURNAL OF MEDICINAL FOOD, vol. 17, no. 2, JPN6025028953, 2014, pages 268 - 277, ISSN: 0005639567 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240162725A (ko) * 2023-05-09 2024-11-18 국립부경대학교 산학협력단 아임계 수 가수분해를 이용한 갑각류 유래 올리고키토산의 제조방법, 이를 이용하여 제조된 올리고키토산 및 올리고키토산을 포함하는 약학적 조성물
KR102906748B1 (ko) 2023-05-09 2025-12-31 국립부경대학교 산학협력단 아임계 수 가수분해를 이용한 갑각류 유래 올리고키토산의 제조방법, 이를 이용하여 제조된 올리고키토산 및 올리고키토산을 포함하는 약학적 조성물

Also Published As

Publication number Publication date
BR112021021699A2 (pt) 2022-03-22
WO2020223698A1 (en) 2020-11-05
CN113766929A (zh) 2021-12-07
EP3962524A1 (en) 2022-03-09
IL287652A (en) 2021-12-01
US20220218822A1 (en) 2022-07-14
AU2020266676A1 (en) 2021-09-30
KR20220004077A (ko) 2022-01-11
EP3962524A4 (en) 2023-06-14
JP2024151337A (ja) 2024-10-24
CA3132653A1 (en) 2020-11-05
BR112021021699A8 (pt) 2023-04-25

Similar Documents

Publication Publication Date Title
JP2024151337A (ja) がんの処置
US20230293427A1 (en) Preparations and compositions comprising polymer combination preparations
CN110121335A (zh) 药物递送组合物及其用途
Hou et al. Engineering a sustained release vaccine with a pathogen-mimicking manner for robust and durable immune responses
CA3193244A1 (en) Compositions and methods of manufacturing amphiphilic block copolymers that form nanoparticles in situ
Wafa et al. Single dose of a polyanhydride particle-based vaccine generates potent antigen-specific antitumor immune responses
US20230398146A1 (en) Immune modulation of myeloid derived suppressive cell function for cancer treatment
US20240082236A1 (en) Cancer therapy
US20240423972A1 (en) Chemotherapeutic bioadhesive particles with immunostimulatory molecules for cancer treatment
KR20240107169A (ko) 핵산 조성물 및 이의 용도
US20250032478A1 (en) Solid forms of resiquimod and formulations thereof
Peres Intracellularly-Targeted Nanoplatform to Target Dendritic Cells and for Immunomodulation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240718

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250227